Langzeittherapie der Schizophrenie

Antipsychotika sind bei Schizophrenie essenziell in der Akutbehandlung. Für die Langzeittherapie gibt es keine klaren Empfehlungen zu Dauer und Dosierung. Das Rückfallrisiko ist unter Medikation geringer, wobei eventuelle Nebenwirkungen überwacht werden müssen. Ein abruptes Absetzen der Medikation ist unbedingt zu vermeiden. Reduktionsversuche sollten nur in kleinen Schritten erfolgen. Psychosoziale Interventionen reduzieren das Rückfallrisiko.

Kernaussagen

• Erkrankungen aus dem schizophrenen Formenkreis gehören zu den häufigsten psychischen Erkrankungen.

• Die medikamentöse Therapie mit Antipsychotika ist ein essenzieller Bestandteil der Akut- und Langzeitbehandlung.

• Leitlinien geben keine eindeutigen Empfehlungen bezüglich Dauer und Dosierung von Antipsychotika in der Langzeittherapie.

• Generell ist das Rückfallrisiko unter Medikation geringer, wobei regelmäßig eventuelle Nebenwirkungen überwacht werden müssen.

• Ein abruptes Absetzen der Medikation sollte unbedingt vermieden werden.

• Reduktionsversuche sollten nur in kleinen Schritten und im Verlauf von Monaten erfolgen.

• Zusätzliche psychosoziale Interventionen reduzieren das Rückfallrisiko.

Schlüsselwörter

Antipsychotika - Dosisreduktion - Rückfallrisiko - Recovery - Depotmedikation - Nebenwirkungen

Publication History

Article published online:
11 November 2022

• Literatur

• 1 Gaebel W, Stricker J, Riesbeck M. The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. Schizophr Res 2020; 225: 4-14 DOI: 10.1016/j.schres.2019.10.049. (PMID: 31806527)
• 2 Kassebaum NJ, Arora M, Barber RM. et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388: 1603-1658
• 3 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301 DOI: 10.1016/S2215-0366(17)30078-0. (PMID: 28237639)
• 4 Haukka J, Suvisaari J, Lönnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry 2003; 160: 460-463 DOI: 10.1176/appi.ajp.160.3.460. (PMID: 12611825)
• 5 Davidson M, Kapara O, Goldberg S. et al. A nation-wide study on the percentage of schizophrenia and bipolar disorder patients who earn minimum wage or above. Schizophr Bull 2016; 42: 443-447 DOI: 10.1093/schbul/sbv023. (PMID: 25796051)
• 6 RKI, Destatis. Krankheitskosten für Deutschland für das Jahr 2015 nach Alter und Geschlecht. Statistisches Bundesamt. 2017 Accessed August 30, 2021 at: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankheitskosten/_inhalt.html
• 7 Kortmann L-M, Müller D, Simic D. et al. Disability Pension and Productivity Loss in Schizophrenia – An Empirical Analysis of the Financial Burden in Germany. Psychiatr Prax 2017; 44: 93-98 DOI: 10.1055/s-0042-104089. (PMID: 27399592)
• 8 Frey S. The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. Eur Psychiatry 2014; 29: 479-489 DOI: 10.1016/j.eurpsy.2014.04.003.
• 9 Robinson D, Woerner MG, Alvir JM. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247 DOI: 10.1001/archpsyc.56.3.241. (PMID: 10078501)
• 10 Delay J, Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. Int Rec Med Gen Pract Clin 1955; 168: 318-326 (PMID: 14381100)
• 11 Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-144 DOI: 10.1111/j.1600-0773.1963.tb01730.x. (PMID: 14060771)
• 12 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet 2019; 394: 939-951 DOI: 10.1016/S0140-6736(19)31135-3.
• 13 Ceraso A, Lin JJ, Schneider-Thoma J. et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020; 2020 DOI: 10.1002/14651858.CD008016.pub3. (PMID: 32840872)
• 14 Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. World Psychiatry 2018; 17: 149-160 DOI: 10.1002/wps.20516. (PMID: 29856543)
• 15 Andreasen NC, Carpenter WT, Kane JM. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. AJP 2005; 162: 441-449 DOI: 10.1176/appi.ajp.162.3.441. (PMID: 15741458)
• 16 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-275 DOI: 10.1093/schbul/13.2.261. (PMID: 3616518)
• 17 Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: 161-170 DOI: 10.1055/s-2006-949513. (PMID: 16944406)
• 18 Liberman R, Kopelowicz A, Ventura J. et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002; 14: 256-272
• 19 Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust NZ J Psychiatry 2003; 37: 586-594 DOI: 10.1046/j.1440-1614.2003.01234.x.
• 20 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007; 64: 1123-1131 DOI: 10.1001/archpsyc.64.10.1123. (PMID: 17909124)
• 21 Correll CU, Solmi M, Veronese N. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017; 16: 163-180 DOI: 10.1002/wps.20420. (PMID: 28498599)
• 22 Tiihonen J, Mittendorfer-Rutz E, Torniainen M. et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. Am J Psychiatry 2016; 173: 600-606 DOI: 10.1176/appi.ajp.2015.15050618. (PMID: 26651392)
• 23 Torrey EF. Surviving schizophrenia: a manual for families, consumers, and providers. 4th ed. New York: Quill; 2001
• 24 Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018; 175: 765-773 DOI: 10.1176/appi.ajp.2018.17091001. (PMID: 29621900)
• 25 Takeuchi H, Siu C, Remington G. et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacol 2019; 44: 1036-1042 DOI: 10.1038/s41386-018-0278-3.
• 26 Emsley R, Asmal L, Rubio JM. et al. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res 2020; 225: 55-62 DOI: 10.1016/j.schres.2019.11.025. (PMID: 31767510)
• 27 Laursen TM, Wahlbeck K, Hällgren J. et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLOS ONE 2013; 8: e67133 DOI: 10.1371/journal.pone.0067133. (PMID: 23826212)
• 28 Torniainen M, Mittendorfer-Rutz E, Tanskanen A. et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41: 656-663 DOI: 10.1093/schbul/sbv181. (PMID: 26818883)
• 29 Rubio JM, Schoretsanitis G, John M. et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry 2020; 7: 749-761 DOI: 10.1016/S2215-0366(20)30264-9. (PMID: 32828165)
• 30 Harrow M, Jobe TH, Faull RN. et al. A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Res 2017; 256: 267-274 DOI: 10.1016/j.psychres.2017.06.069. (PMID: 28651219)
• 31 Wunderink L, Nienhuis FJ, Sytema S. et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-661 DOI: 10.4088/jcp.v68n0502. (PMID: 17503973)
• 32 Wunderink L, Nieboer RM, Wiersma D. et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-920 DOI: 10.1001/jamapsychiatry.2013.19. (PMID: 23824214)
• 33 Ran M-S, Weng X, Chan CL-W. et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015; 207: 495-500
• 34 Gaebel W, Hasan A, Falkai P. S3-Leitlinie Schizophrenie. Berlin [Heidelberg]: Springer; 2019
• 35 Taipale H, Tanskanen A, Mehtälä J. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61-68 DOI: 10.1002/wps.20699.
• 36 Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-226 DOI: 10.1002/wps.20060. (PMID: 24096780)
• 37 Higgins JPT, Welton NJ. Network meta-analysis: A norm for comparative effectiveness?. Lancet 2015; 386: 628-630 DOI: 10.1016/S0140-6736(15)61478-7. (PMID: 26334141)
• 38 Schneider-Thoma J, Chalkou K, Dörries C. et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. The Lancet 2022; 399: 824-836 DOI: 10.1016/S0140-6736(21)01997-8.
• 39 Alvarez-Jimenez M, Priede A, Hetrick SE. et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012; 139: 116-128 DOI: 10.1016/j.schres.2012.05.007. (PMID: 22658527)
• 40 Misawa F, Kishimoto T, Hagi K. et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res 2016; 176: 220-230 DOI: 10.1016/j.schres.2016.07.018. (PMID: 27499361)
• 41 Kishimoto T, Hagi K, Kurokawa S. et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8: 387-404 DOI: 10.1016/S2215-0366(21)00039-0. (PMID: 33862018)
• 42 Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116: 515-523 DOI: 10.1016/0002-8703(88)90627-8. (PMID: 2899971)
• 43 Silvestri S, Seeman MV, Negrete JC. et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacol (Berl) 2000; 152: 174-180 DOI: 10.1007/s002130000532.
• 44 Chouinard G, Samaha A-N, Chouinard V-A. et al. Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189-219 DOI: 10.1159/000477313. (PMID: 28647739)
• 45 Meltzer HY, Lee MA, Ranjan R. et al. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacol (Berl) 1996; 124: 176-187 DOI: 10.1007/BF02245619. (PMID: 8935814)
• 46 Schneider-Thoma J, Chalkou K, Dörries C. et al. Comparative efficacy and tolerability of 31 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 2022; 399: 824-836 DOI: 10.1016/S0140-6736(21)01997-8. (PMID: 35219395)
• 47 Schneider-Thoma J, Efthimiou O, Bighelli I. et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6: 753-765 DOI: 10.1016/S2215-0366(19)30223-8. (PMID: 31320283)
• 48 Ray WA, Chung CP, Murray KT. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235 DOI: 10.1056/NEJMoa0806994. (PMID: 19144938)
• 49 Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009; 23: 837-855 DOI: 10.2165/11314280-000000000-00000. (PMID: 19739694)
• 50 Tek C, Kucukgoncu S, Guloksuz S. et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Intervention in Psychiatry 2016; 10: 193-202 DOI: 10.1111/eip.12251. (PMID: 25962699)
• 51 Takeuchi H, Suzuki T, Remington G. et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 2013; 39: 993-998 DOI: 10.1093/schbul/sbt090. (PMID: 23821768)
• 52 Zhang W, Deng W, Yao L. et al. Brain structural abnormalities in a group of never-medicated patients with long-term schizophrenia. Am J Psychiatry 2015; 172: 995-1003 DOI: 10.1176/appi.ajp.2015.14091108. (PMID: 26085040)
• 53 Andreasen NC, Liu D, Ziebell S. et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609-615 DOI: 10.1176/appi.ajp.2013.12050674. (PMID: 23558429)
• 54 Emsley R, Asmal L, du Plessis S. et al. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. Psychol Med 2017; 47: 2187-2196 DOI: 10.1017/S0033291717000642. (PMID: 28347393)
• 55 Leucht S, Bauer S, Siafis S. et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: A meta-analysis. JAMA Psychiatry 2021; 78: 1238-1248 DOI: 10.1001/jamapsychiatry.2021.2130. (PMID: 34406325)
• 56 Leucht S, Tardy M, Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-2071 DOI: 10.1016/S0140-6736(12)60239-6. (PMID: 22560607)
• 57 Bogers JPAM, Hambarian G, Michiels M. et al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in Patients with chronic schizophrenia: A systematic review and meta-analysis. Schizophr Bull Open 2020; 1: sgaa002 DOI: 10.1093/schizbullopen/sgaa002.
• 58 Sampson S, Mansour M, Maayan N. et al. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 2013; DOI: 10.1002/14651858.CD006196.pub2. (PMID: 23881657)
• 59 Kane JM, Davis JM, Schooler N. et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159: 554-560 DOI: 10.1176/appi.ajp.159.4.554. (PMID: 11925292)
• 60 Huhn M, Leucht C, Rothe P. et al. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. Eur Arch Psychiatry Clin Neurosci 2021; 271: 293-302 DOI: 10.1007/s00406-020-01109-y. (PMID: 32062728)
• 61 Horowitz MA, Jauhar S, Natesan S. et al. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull 2021; 47: 1116-1129 DOI: 10.1093/schbul/sbab017. (PMID: 33754644)
• 62 Jääskeläinen E, Juola P, Hirvonen N. et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296-1306 DOI: 10.1093/schbul/sbs130. (PMID: 23172003)
• 63 Bighelli I, Rodolico A, García-Mieres H. et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry 2021; 8: 969-980 DOI: 10.1016/S2215-0366(21)00243-1. (PMID: 34653393)
• 64 Alvarez-Jimenez M, Koval P, Schmaal L. et al. The Horyzons project: a randomized controlled trial of a novel online social therapy to maintain treatment effects from specialist first-episode psychosis services. World Psychiatry 2021; 20: 233-243 DOI: 10.1002/wps.20858. (PMID: 34002511)